101 related articles for article (PubMed ID: 36805183)
1. Comparative Genomic Profiling of Second Breast Cancers following First Ipsilateral Hormone Receptor-Positive Breast Cancers.
Rassy E; Garberis I; Tran-Dien A; Job B; Chung-Scott V; Bouakka I; Bassil J; Ferkh R; Lacroix-Triki M; Zanconati F; Giudici F; Generali D; Rouleau E; Lacroix L; Andre F; Pistilli B
Clin Cancer Res; 2023 May; 29(9):1822-1831. PubMed ID: 36805183
[TBL] [Abstract][Full Text] [Related]
2. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
3. Comparative genomic analysis reveals bilateral breast cancers are genetically independent.
Song F; Li X; Song F; Zhao Y; Li H; Zheng H; Gao Z; Wang J; Zhang W; Chen K
Oncotarget; 2015 Oct; 6(31):31820-9. PubMed ID: 26378809
[TBL] [Abstract][Full Text] [Related]
4. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
5. High-resolution mapping of DNA breakpoints to define true recurrences among ipsilateral breast cancers.
Bollet MA; Servant N; Neuvial P; Decraene C; Lebigot I; Meyniel JP; De Rycke Y; Savignoni A; Rigaill G; Hupé P; Fourquet A; Sigal-Zafrani B; Barillot E; Thiery JP
J Natl Cancer Inst; 2008 Jan; 100(1):48-58. PubMed ID: 18159071
[TBL] [Abstract][Full Text] [Related]
6. Different Array CGH profiles within hereditary breast cancer tumors associated to BRCA1 expression and overall survival.
Alvarez C; Aravena A; Tapia T; Rozenblum E; Solís L; Corvalán A; Camus M; Alvarez M; Munroe D; Maass A; Carvallo P
BMC Cancer; 2016 Mar; 16():219. PubMed ID: 26979459
[TBL] [Abstract][Full Text] [Related]
7. Assessment of DNA methylation profiling and copy number variation as indications of clonal relationship in ipsilateral and contralateral breast cancers to distinguish recurrent breast cancer from a second primary tumour.
Huang KT; Mikeska T; Li J; Takano EA; Millar EK; Graham PH; Boyle SE; Campbell IG; Speed TP; Dobrovic A; Fox SB
BMC Cancer; 2015 Oct; 15():669. PubMed ID: 26452468
[TBL] [Abstract][Full Text] [Related]
8. Molecular features of untreated breast cancer and initial metastatic event inform clinical decision-making and predict outcome: long-term results of ESOPE, a single-arm prospective multicenter study.
Callens C; Driouch K; Boulai A; Tariq Z; Comte A; Berger F; Belin L; Bièche I; Servois V; Legoix P; Bernard V; Baulande S; Chemlali W; Bidard FC; Fourchotte V; Salomon AV; Brain E; Lidereau R; Bachelot T; Saghatchian M; Campone M; Giacchetti S; Zafrani BS; Cottu P
Genome Med; 2021 Mar; 13(1):44. PubMed ID: 33722295
[TBL] [Abstract][Full Text] [Related]
9. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations.
Holstege H; Horlings HM; Velds A; Langerød A; Børresen-Dale AL; van de Vijver MJ; Nederlof PM; Jonkers J
BMC Cancer; 2010 Nov; 10():654. PubMed ID: 21118481
[TBL] [Abstract][Full Text] [Related]
10. Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays.
Yang XR; Killian JK; Hammond S; Burke LS; Bennett H; Wang Y; Davis SR; Strong LC; Neglia J; Stovall M; Weathers RE; Robison LL; Bhatia S; Mabuchi K; Inskip PD; Meltzer P
PLoS One; 2015; 10(3):e0116078. PubMed ID: 25764003
[TBL] [Abstract][Full Text] [Related]
11. An array CGH based genomic instability index (G2I) is predictive of clinical outcome in breast cancer and reveals a subset of tumors without lymph node involvement but with poor prognosis.
Bonnet F; Guedj M; Jones N; Sfar S; Brouste V; Elarouci N; Banneau G; Orsetti B; Primois C; de Lara CT; Debled M; de Mascarel I; Theillet C; Sévenet N; de Reynies A; MacGrogan G; Longy M
BMC Med Genomics; 2012 Nov; 5():54. PubMed ID: 23186559
[TBL] [Abstract][Full Text] [Related]
12. High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer.
Johansson I; Nilsson C; Berglund P; Strand C; Jönsson G; Staaf J; Ringnér M; Nevanlinna H; Barkardottir RB; Borg A; Olsson H; Luts L; Fjällskog ML; Hedenfalk I
Breast Cancer Res Treat; 2011 Oct; 129(3):747-60. PubMed ID: 21113657
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.
Jardim DL; Conley A; Subbiah V
Orphanet J Rare Dis; 2013 Jul; 8():112. PubMed ID: 23895135
[TBL] [Abstract][Full Text] [Related]
14. The use of ultra-dense array CGH analysis for the discovery of micro-copy number alterations and gene fusions in the cancer genome.
Przybytkowski E; Ferrario C; Basik M
BMC Med Genomics; 2011 Jan; 4():16. PubMed ID: 21272361
[TBL] [Abstract][Full Text] [Related]
15. Genomic comparison of early-passage conditionally reprogrammed breast cancer cells to their corresponding primary tumors.
Mahajan AS; Sugita BM; Duttargi AN; Saenz F; Krawczyk E; McCutcheon JN; Fonseca AS; Kallakury B; Pohlmann P; Gusev Y; Cavalli LR
PLoS One; 2017; 12(10):e0186190. PubMed ID: 29049316
[TBL] [Abstract][Full Text] [Related]
16. The use of molecular assays to establish definitively the clonality of ipsilateral breast tumor recurrences and patterns of in-breast failure in patients with early-stage breast cancer treated with breast-conserving therapy.
Vicini FA; Antonucci JV; Goldstein N; Wallace M; Kestin L; Krauss D; Kunzmann J; Gilbert S; Schell S
Cancer; 2007 Apr; 109(7):1264-72. PubMed ID: 17372920
[TBL] [Abstract][Full Text] [Related]
17. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
18. Combined tumor genomic profiling and exome sequencing in a breast cancer family implicates ATM in tumorigenesis: A proof of principle study.
Bubien V; Bonnet F; Dupiot-Chiron J; Barouk-Simonet E; Jones N; de Reynies A; MacGrogan G; Sevenet N; Letouzé E; Longy M
Genes Chromosomes Cancer; 2017 Nov; 56(11):788-799. PubMed ID: 28691344
[TBL] [Abstract][Full Text] [Related]
19. Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial.
Guerini-Rocco E; Gray KP; Fumagalli C; Reforgiato MR; Leone I; Rafaniello Raviele P; Munzone E; Kammler R; Neven P; Hitre E; Jerusalem G; Simoncini E; Gombos A; Deleu I; Karlsson P; Aebi S; Chirgwin J; Di Lauro V; Thompson A; Graas MP; Barber M; Fontaine C; Loibl S; Gavilá J; Kuroi K; Müller B; O'Reilly S; Di Leo A; Goldhirsch A; Viale G; Barberis M; Regan MM; Colleoni M
Clin Cancer Res; 2021 Jan; 27(2):504-512. PubMed ID: 33082214
[TBL] [Abstract][Full Text] [Related]
20. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer.
Chae YK; Davis AA; Jain S; Santa-Maria C; Flaum L; Beaubier N; Platanias LC; Gradishar W; Giles FJ; Cristofanilli M
Mol Cancer Ther; 2017 Jul; 16(7):1412-1420. PubMed ID: 28446639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
